MedTrace Logo

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

NCT02931838 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 268

Last updated 2020-11-27

Study results available
· View outcomes & findings →

Summary

A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165

Conditions

Interventions

DRUG

BMS-986165

DRUG

Placebo for BMS-986165

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-15
Primary Completion
2017-11-16
Completion
2017-11-16
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Japan
  • Latvia
  • Mexico
  • Poland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02931838 on ClinicalTrials.gov